Drugs / Centhaquine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04056065 | May 2017 → Sep 2018 | — | Pharmazz, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05251181 | Feb → Oct 2026 expected | — | Pharmazz, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04045327 | Jan → Sep 2019 | — | Pharmazz, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05956418 | Aug 2021 → Jun 2026 overdue | — | Pharmazz, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05241067 Comparator | May → Oct 2026 expected | acute respiratory distress syndrome | Pharmazz, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Centhaquine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04056065 ↗ |
| Known as | centhaquin | “Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective...” NCT04045327 ↗1“Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine)” NCT04056065 ↗ |
| Known as | Lyfaquin | “A Multicentric, Randomized, Controlled Phase III Study of Centhaquine
(Lyfaquin(®)) as a Resuscitative Agent in Hypovolemic Shock Patients.” PMID 34061314 ↗ Jun 20211“Resuscitative Effect of Centhaquine (Lyfaquin(®)) in Hypovolemic Shock Patients” PMID 33970455 ↗ May 2021 |
| Route | Intravenous | “Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.” NCT04045327 ↗ |